Business
GMT: Patent expansion, cost cuts, and narrowed loss set the stage for commercialization in 2026
GMT: Patent expansion, cost cuts, and narrowed loss set the stage for commercialization in 2026
About this update from Genomtec Sa
2025 saw major organizational changes, patent expansion, and cost reductions, with a narrowed net loss and increased equity. Commercialization of key projects is the main focus, supported by grants and new share issues, while risks remain tied to early-stage development and funding needs.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.